Eli Lilly and Company (LLY)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Diabetes/Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 9/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.85% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Why the traditional 60/40 portfolio might be dead
- Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
- Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound
- What Does Eli Lilly (LLY) Gain From This $870 Million Drug Discovery Deal?
- Why You Should Think About Eli Lilly Stock Differently Now
- Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
- Lilly’s Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Eli Lilly and Company.
Full LLY Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.